Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2025)

BioNexus Gene Lab's Invested Capital history spans 8 years, with the latest figure at $8.6 million for Q4 2025.

  • Quarterly results put Invested Capital at $8.6 million for Q4 2025, up 3.51% from a year ago — trailing twelve months through Dec 2025 was $8.6 million (up 3.51% YoY), and the annual figure for FY2025 was $8.6 million, up 3.51%.
  • Invested Capital for Q4 2025 was $8.6 million at BioNexus Gene Lab, up from $6.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $9.7 million in Q4 2023 to a low of $5.6 million in Q2 2023.
  • The 5-year median for Invested Capital is $7.2 million (2021), against an average of $7.7 million.
  • The sharpest move saw Invested Capital soared 70.7% in 2024, then dropped 27.4% in 2025.
  • Year by year, Invested Capital stood at $7.2 million in 2021, then decreased by 7.61% to $6.7 million in 2022, then soared by 44.9% to $9.7 million in 2023, then decreased by 13.82% to $8.3 million in 2024, then increased by 3.51% to $8.6 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $8.6 million, $6.8 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.